ClinicalTrials.gg
RecruitingNCT05698628DECIDE-ECMOUpdated Jun 15, 2023

Distal Perfusion Timing, Early or Conservative, to Prevent Limb Ischemia During Peripheral VA-ECMO

An interventional study of Distal perfusion catheterization in Extracorporeal Membrane Oxygenation Complication, sponsored by Min-Seok Kim. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2023-06-15.

Sponsored by Min-Seok Kim · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Shock, Cardiogenic with a site in Korea, Republic of — 8 open to participants now, 8 under way, none of them phase 3. Shock, Cardiogenic · Korea, Republic of.

Planned enrollment
5th of 10
400 · median 280
Started
2023
the only one that year
No phase
8 of 13
5 open now
Registered
8th of 13
by date
Lead sponsor
2 of 13
Min-Seok Kim

Among the 13 studies in Shock, Cardiogenic with a site in Korea, Republic of, this one is the 5th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2023, is one of 8 with no phase, and was the 8th registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

8 of the 13 studies in Shock, Cardiogenic with a site in Korea, Republic of are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Shock, Cardiogenic with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Peripheral VA-ECMO is widely used in refractory cardiogenic shock patients as a salvage therapy. In most cases, the femoral artery and vein are used for the vascular approach. Large cannulas are usually used for proper oxygenation, which may cause peripheral limb ischemia. Distal perfusion catheterization (DPC) at the ipsilateral arterial cannula site is recommended to prevent distal limb ischemia. However, there is no consensus on the proper timing of DPC and additional invasive procedures may cause complications during VA-ECMO support. In this analysis, the investigators compare the clinical outcomes of distal limb ischemia complications between the conventional DPC group (DPC at the time of limb ischemia sign) and the preemptive DPC group (DPC at the time of VA-ECMO application).

03

Conditions studied

  • Extracorporeal Membrane Oxygenation Complication

Browse trials for

Keywords

  • Extracorporeal Membrane Oxygenation
  • Limb ischemia
  • Cardiogenic shock
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥19 years old
  • cardiogenic shock with peripheral VA-ECMO

Exclusion criteria

Exclusion Criteria:

  • Unwilling or unable to obtain from the participant or substitute decision-maker
  • Patients who are currently pregnant, postpartum period within 30 days or are breast-feeding
  • VA-ECMO application for causes other than cardiogenic shock
  • Severe coagulopathy
  • Irreversible limb ischemia requiring interventional procedures or surgery at the time of VA-ECMO (previously diagnosed ASO(atherosclerosis obliterans) patients)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Preemptive distal perfusion group

    Distal perfusion catheterization will be done within 1 hour after VA-ECMO application.

    Procedure: Distal perfusion catheterization

  • Active comparator
    Conventional distal perfusion group

    The conventional group will undergo distal perfusion catheterization at the time of limb ischemia sign.

    Procedure: Distal perfusion catheterization

Interventions

  • ProcedureDistal perfusion catheterization

    Distal perfusion catheterization will be done within 1 hour after the VA-ECMO application in the preemptive DPC group. The conventional DPC group will undergo distal perfusion catheterization at the time of limb ischemia sign.

06

What researchers measure

Primary outcomes

  1. Limb ischemia

    Limb ischemia requiring surgical/percutaneous procedure or resulting necrosis or neurologic sequelae in the distal limb during hospitalization

    Time frame: From date of randomization until the date of discharge or assessed up to 90 days

Secondary outcomes

  1. All-cause mortality

    All-cause of death

    Time frame: From date of randomization until the date of death from any cause, assessed up to 12 months

  2. Successful ECMO weaning

    Having ECMO removed and not requiring further mechanical support because of recurring cardiogenic shock over the following 30 days

    Time frame: From date of randomization until the date of discharge or assessed up to 90 days

  3. ECMO related complications

    Bleeding, systemic thromboembolism, etc.

    Time frame: From date of randomization until the date of ECMO removal, assesed up to 90 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Feb 2027, 46 months after the start.

Of 48 non-industry interventional studies with no phase under Shock, Cardiogenic, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 46 months is above that.

Counting every sponsor, half of 52 studies reached it within 39 months; a quarter within 24 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2023
First posted
Jan 26, 2023
StartActual
Apr 28, 2023
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2027
Last update
Jun 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05698628
Lead sponsor
Min-Seok Kim
Responsible party
Min-Seok Kim (Clinical Associate Professor, Asan Medical Center) — Sponsor-investigator
First posted
Jan 26, 2023
Start date
Apr 28, 2023
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Jun 15, 2023

Study contacts

Min-Seok Kim, PhD
Contact
msk@amc.seoul.kr
82-2-3010-3948
Ah-Ram Kim, MD
Contact
ahram3256@amc.seoul.kr
82-2-3010-0111
Min-Seok Kim
study chair · Asan Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion